Haematological Malignancies

• ESMO E-Learning: Treatment of Multiple Myeloma Patients
• What is the best regiment and sequencing for treatment of mantle cell lymphoma
• Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup...
• Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
• Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
• Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis
• Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early resp...
• Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a t...
• Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB p...
• MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
• Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
• Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
• Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
• Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
• A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
• Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
• Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
• A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
• Can "Superman" have Chronic Myelomonocytic Leukemia?
• Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
• Vaccinating your cancer patients - When to vaccinate your solid tumour patient and health care professionals
• Advances in the management of the NK-T cell lymphomas
• What is new in the classification and management of DLBCL in 2019
• Novel management of follicular lymphoma based on biological insights and novel concepts
• TET2 and DNA methylation in hematopoietic transformation

• « Previous
• 1
• 2
• ...
• 43
• Next »